Neuromodulation uses electrical stimuli to alter neurotransmission in storage and emptying disorders — most importantly sacral neuromodulation and percutaneous tibial nerve stimulation for refractory OAB and non-obstructive retention.
Principles
Neurostimulation produces an immediate response; neuromodulation alters neurotransmission. The putative mechanism of sacral neuromodulation is activation of somatic sacral afferent inflow at the sacral root, which modulates the storage/emptying reflexes in the bladder and CNS — in OAB it modulates sensory outflow to the PMC to prevent involuntary contractions, and in retention it inhibits the guarding reflex.
Patient Selection
Neuromodulation is tried when conservative measures fail and before invasive surgery (enterocystoplasty, diversion); no UDS finding predicts response. Contraindications — absolute: significant spine/sacral anatomic abnormalities, cognitive dysfunction, physical limitations preventing pelvic-organ function, non-compliance; relative: pregnancy and MRI (older devices preclude spinal/below-head MRI; turn devices off; for elective MRI the device is often removed and replaced).
Sacral Neuromodulation (SNS)
- FDA-approved indications: non-obstructive urinary retention, urinary urge incontinence, urgency-frequency syndrome, and chronic fecal incontinence. Not FDA-approved for symptoms from known neuropathy (MS, Parkinson, SCI, pelvic-nerve injury).
- Technique (two stages): Stage I is a trial of an external lead in the S3 foramen (located ~9 cm cephalad from the sacral drop-off, 1–2 cm lateral to midline); Stage II implants the pulse generator if there is >50% improvement. Trial length: 1–2 weeks for urgency-frequency/UUI, 3–4+ weeks for retention.
| Nerve root | Motor response | Sensory response |
|---|---|---|
| S2 | Plantarflexion of the entire foot with lateral rotation; anal clamp | Leg and thigh |
| S3 | Plantarflexion of the great toe + bellows reflex (anal wink/levator contraction) | Pulling in the rectum, scrotum, or vagina |
| S4 | Bellows reflex only | Pulling in the rectum only |
Selective Nerve Stimulation
- Percutaneous tibial nerve stimulation (PTNS) — the tibial nerve (L4–S3) modulates pelvic-floor/bladder/sphincter nerves; improves OAB similarly to antimuscarinics with a better adverse-effect profile; third-line OAB therapy (2019 AUA) for patients willing to attend frequent sessions (its main limitation); FDA-approved. AEs: stimulation discomfort and minor insertion-site bleeding.
- Pudendal and dorsal genital nerve stimulation are alternative afferent targets being studied.
OnabotulinumtoxinA vs Sacral Neuromodulation
OnabotulinumtoxinA is not ideal with emptying disorders or retention risk (if the patient won't catheterize) and needs retreatment ~every 6 months; sacral neuromodulation is less attractive in neurogenic conditions, for patients unwilling to undergo an implant, or who may need future MRIs.
Electrical Stimulation for Emptying
- Sacral rhizotomy/anterior root stimulation: S3 provides the dominant motor innervation of the bladder; posterior rhizotomy reduces reflex detrusor activity and improves compliance; the Brindley stimulator uses post-stimulus voiding (the sphincter relaxes faster than the detrusor between pulse trains).
- Sacral neuromodulation is successful for idiopathic non-obstructive retention, post-hysterectomy deafferentation retention, and Fowler syndrome.
Complications and Troubleshooting
- The most common test-stimulation complication is lead migration (12%); the most common post-implant complication is pain (15% at 12 months); surgical revision in ~33%, explant for inefficacy in ~10%; infection is managed by explanting the whole system.
- Impedance (normal 400–1500 ohms) checks integrity: open circuit (fractured lead/loose connection) → high impedance (>4000 ohms), identified on unipolar testing, no stimulation; short circuit (fluid intrusion/crushed wires) → low impedance (<50 ohms), identified on bipolar testing. For pocket vs output discomfort, turn the device off — if discomfort persists it is pocket-related.
Self-Test
1. What is the putative mechanism of action of neuromodulation? Activation of somatic sacral afferent inflow at the sacral root, modulating the bladder's storage/emptying reflexes — preventing involuntary contractions in OAB and inhibiting the guarding reflex in retention.
2. What are the contraindications to neuromodulation? Absolute: significant spine/sacral anatomic abnormalities, cognitive dysfunction, physical limitations preventing pelvic-organ function, non-compliance. Relative: pregnancy and the need for MRI.
3. What are the S3 motor and sensory responses on lead placement? Motor — plantarflexion of the great toe and the bellows reflex (anal wink); sensory — pulling/paresthesia in the rectum, scrotum, or vagina.